No Data
Chinese Drug Regulator Accepts Clinical Trial Application of Cosunter Pharmaceutical's Unit for Two Drugs
Fujian Cosunter Pharmaceutical (SZSE:300436) Is Making Moderate Use Of Debt
Fujian Cosunter Pharmaceutical (300436.SZ): The clinical trial application for the Innovative Drugs GST-HG131 combined with GST-HG141 for the treatment of hepatitis B in previously treated patients has been accepted.
On March 17, Gronghui reported that Fujian Cosunter Pharmaceutical (300436.SZ) announced that its Innovative Drugs holding subsidiary, Fujian Guosheng Zhonglin Biotechnology Co., Ltd. (referred to as "Guosheng Zhonglin"), recently received the Acceptance Notice for the clinical trial application from the National Medical Products Administration regarding the hepatitis B treatment Innovative Drug GST-HG131 in conjunction with GST-HG141. This is intended to challenge the clinical cure of hepatitis B in patients with nucleos(t)ide analogues (NUC) treatment history. The aforementioned Phase II clinical study has recently been included in the pilot project for optimizing the review and approval of Innovative Drugs clinical trials, which will effectively shorten the review process for this clinical trial application.
GTJA: Continuous iteration of anti-tumor therapies, domestic new drugs welcome breakthroughs.
GTJA focuses on products with significant differentiation advantages and leading companies in innovative segments.
Fujian Cosunter Pharmaceutical (300436.SZ) subsidiary GST-HG131, in conjunction with GST-HG141, has received the confirmation letter for the pilot project for optimized review and approval of Phase II clinical research.
Fujian Cosunter Pharmaceutical (300436.SZ) announced that on March 10, 2025, the company's Innovative Drugs holding subsidiary Fujian...
Individual Investors Among Fujian Cosunter Pharmaceutical Co., Ltd.'s (SZSE:300436) Largest Stockholders and Were Hit After Last Week's 7.0% Price Drop
Fujian Cosunter Pharmaceutical Co., Ltd.'s (SZSE:300436) Popularity With Investors Under Threat As Stock Sinks 25%
